12 analysts have shared their evaluations of Sarepta Therapeutics (NASDAQ:SRPT) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a ...

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a ...

Among these, Sarepta Therapeutics crashed following a report of a patient's death after treatment with Elevidys. Incyte also declined after study data disappointed investors. Shares of Sarepta ...

In the last three months, 8 analysts have published ratings on Sarepta Therapeutics (NASDAQ:SRPT), offering a diverse range of perspectives from bullish to bearish. The table below offers a ...

Sarepta Therapeutics SRPT shares soared 8.7% in the last trading session to close at $79.97. The move was backed by solid volume with far more shares changing hands than in a normal session.

Sarepta Therapeutics (SRPT) came out with quarterly earnings of $1.50 per share, missing the Zacks Consensus Estimate of $1.87 per share. This compares to earnings of $0.47 per share a year ago.

Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Sarepta Therapeutics (BMV:SRPT) with a Sector Perform recommendation. There are 956 funds or institutions reporting positions ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s stock price traded down 4% during trading on Thursday after ...

SAREPTA THERAPEUTICS ($SRPT) posted quarterly earnings results on Wednesday, February 26th. The company reported earnings of $1.50 per share, missing estimates of $1. ...

Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Sector Perform recommendation. As of March 3, 2025, the average one-year price ...

The price trend for Sarepta Therapeutics (SRPT) has been bearish lately and the stock has lost 9% over the past four weeks. However, the formation of a hammer chart pattern in its last trading ...

Cantor Fitzgerald reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a ...